Integration of the FOXA1 knockdown-induced and drug-induced gene expression profiles identified 63 candidate compounds for treatment of breast cancer, including 18 approved drugs, with recovery of the known breast cancer therapy fulvestrant. The gene discussed is FOXA1; the disease is breast cancer.